Investors & Media

    Print Page     Close Window     

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Flex Pharma Announces Pricing Of Initial Public Offering

Boston, MA – Flex Pharma, Inc., a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Flex Pharma. In addition, the company has granted the underwriters a 30-day option to purchase from the company, at the public offering price, less underwriting discounts and commissions, up to an additional 810,000 shares of common stock. Flex Pharma’s shares of common stock have been approved for listing on the NASDAQ Global Market and are expected to begin trading on Thursday, January 29, 2015 under the ticker symbol “FLKS.”

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers. JMP Securities LLC is acting as lead manager and Cantor Fitzgerald & Co. and Roth Capital Partners, LLC are acting as co-managers in the proposed offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 28, 2015. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. In the second quarter of 2015, the Company intends to initiate at least one human proof-of-concept study of its proprietary treatment for individuals with nocturnal leg cramps.

Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Contact:
Elizabeth Woo
VP, Investor Relations & Corporate Communications
Flex Pharma, Inc.
irdept@flex-pharma.com
617-874-1829